Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 9INDUSTRY 3NETWORK 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gynecologic 1Breast 1

Conditions

Neoplasms 3Skin Diseases 2Neoplasms by Site 2Carcinoma, Renal Cell 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Prostatic Neoplasms 1Precancerous Conditions 1Neoplasm Metastasis 1Kidney Neoplasms 1Hematologic Diseases 1Genital Neoplasms, Female 1Genital Diseases, Female 1Genital Diseases 1Female Urogenital Diseases and Pregnancy Complications 1Communicable Diseases 1Breast Neoplasms 1Breast Diseases 1Autoimmune Diseases 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Watchful Waiting × Clear all
NCT06815939 2026-01-29

OPTICS

DL Analytics

Phase NA Recruiting
10,000 enrolled
GynecologicOther neoplasm

Urogenital Diseases, Genital Diseases, Uterine Cervical Diseases, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Precancerous Conditions, Urogenital Neoplasms, Uterine Diseases, Uterine Neoplasms

NCT05080907 2022-11-09

Collection and Distribution of Biospecimens for Novel Research

iSpecimen Inc

Unknown
100,000 enrolled

Autoimmune Diseases, Communicable Diseases, Hematologic Diseases, Neoplasms, Skin Diseases

NCT04016935 2022-05-17

EndoPredict® Extended Endocrine Trial (EXET)

Myriad Genetic Laboratories, Inc.

Terminated
855 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡